Urate-lowering therapy following a treat-to-target continuation strategy compared to a treat-to-avoid-symptoms discontinuation strategy in gout patients in remission (GO TEST Finale): study protocol of a multicentre pragmatic randomized superiority trial.
Iris Rose PeetersAlfons A den BroederWilliam J TaylorNathan den BroederMarcel FlendrieNoortje van HerwaardenPublished in: Trials (2023)
International Clinical Trial Registry Platform (ICTRP) NL9245. Registered on 2 February 2021 (METC Oost-Nederland NL74350.091.20); EudraCT EUCTR2020-005730-15-NL. Registered on 11 January 2021.
Keyphrases
- study protocol
- clinical trial
- double blind
- open label
- phase iii
- phase ii
- randomized controlled trial
- end stage renal disease
- placebo controlled
- ejection fraction
- chronic kidney disease
- newly diagnosed
- prognostic factors
- peritoneal dialysis
- uric acid
- stem cells
- mesenchymal stem cells
- high throughput
- rheumatoid arthritis
- cross sectional
- patient reported outcomes
- disease activity